Study Details | To investigate the efficacy and safety of LNP023 compared with rituximab in the treatment of subjects with idiopathic membranous nephropathy |
Protocol Number | CLNP023D12201 |
Phase | II |
Therapeutic Area | Nephrology |
Subject Types | With Medical Condition |
Indication | Idiopathic membranous nephropathy |
Principal Investigator | A/Prof Jimmy Teo Boon Wee |
Investigator Product / Device | LNP023 |
Sponsor | Novartis Singapore Pte Ltd |